LYTIX Stock Overview
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lytix Biopharma AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr5.86 |
| 52 Week High | kr14.40 |
| 52 Week Low | kr4.60 |
| Beta | -0.55 |
| 1 Month Change | -4.87% |
| 3 Month Change | -18.04% |
| 1 Year Change | -13.82% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -68.49% |
Recent News & Updates
Recent updates
We're A Little Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate
Mar 02
We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate
Oct 04We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth
Jun 21Companies Like Lytix Biopharma (OB:LYTIX) Are In A Position To Invest In Growth
Jan 11We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate
Jul 16We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate
Jan 25We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth
Sep 14Shareholder Returns
| LYTIX | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | 2.4% | 3.0% | -0.7% |
| 1Y | -13.8% | -65.7% | 5.3% |
Return vs Industry: LYTIX exceeded the Norwegian Biotechs industry which returned -65.7% over the past year.
Return vs Market: LYTIX underperformed the Norwegian Market which returned 5.3% over the past year.
Price Volatility
| LYTIX volatility | |
|---|---|
| LYTIX Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in NO Market | 10.2% |
| 10% least volatile stocks in NO Market | 3.0% |
Stable Share Price: LYTIX's share price has been volatile over the past 3 months.
Volatility Over Time: LYTIX's weekly volatility has decreased from 17% to 9% over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Oystein Rekdal | www.lytixbiopharma.com |
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company’s products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase.
Lytix Biopharma AS Fundamentals Summary
| LYTIX fundamental statistics | |
|---|---|
| Market cap | kr234.80m |
| Earnings (TTM) | -kr87.94m |
| Revenue (TTM) | kr10.24m |
22.9x
P/S Ratio-2.7x
P/E RatioIs LYTIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LYTIX income statement (TTM) | |
|---|---|
| Revenue | kr10.24m |
| Cost of Revenue | kr0 |
| Gross Profit | kr10.24m |
| Other Expenses | kr98.18m |
| Earnings | -kr87.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | -2.19 |
| Gross Margin | 100.00% |
| Net Profit Margin | -858.68% |
| Debt/Equity Ratio | 0% |
How did LYTIX perform over the long term?
See historical performance and comparison